Alogliptin benzoate

• CAT Number: I005101
• CAS Number: 850649-62-6
• Molecular Formula: C₁₈H₂₁N₅O₂.C₇H₆O₂
• Molecular Weight: 461.52
• Purity: ≥95%
• Synonyms: 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]benzonitrile;benzoic acid
• Target: Apoptosis
• Solubility: 10 mM in DMSO
• Storage: 3 years -20C powder
• IC50: <10 nM
• InChI: InChI=1S/C18H21N5O2.C7H6O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19;8-7(9)6-4-2-1-3-5-6/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3;1-5H,(H,8,9)/t15-;/m1./s1
• InChIKey: KEJICOXJTRHYAK-XFULWGLBSA-N
• SMILES: CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCC[C@H](C3)N.C1=CC=C(C=C1)C(=O)O

Alogliptin benzoate（Cat No.:I005101）is a selective dipeptidyl peptidase-4 (DPP-4) inhibitor used to manage type 2 diabetes by regulating blood glucose levels. By inhibiting DPP-4, alogliptin increases the levels of incretin hormones, which enhance insulin secretion and suppress glucagon release in a glucose-dependent manner. This action improves glycemic control without significant hypoglycemia risk. Alogliptin’s specificity for DPP-4 makes it a valuable agent in diabetes management, either alone or in combination with other therapies. It is widely researched for its efficacy, safety, and impact on metabolic health.

Reference

[1]. Rendell M, et al. Alogliptin benzoate for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2012 Mar;13(4):553-63.
[2]. Radha Andukuri, et al. Alogliptin: a new addition to the class of DPP-4 inhibitors. Diabetes Metab Syndr Obes. 2009; 2: 117-126.
[3]. Takeuchi K, et al. Pharmacological and clinical profile of alogliptin benzoate (NESINA?).Nihon Yakurigaku Zasshi. 2011 Jan;137(1):43-50.
[4]. Moritoh Y, et al. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice. Eur J Pharmacol. 2008 Jul 7;588(2-3):325-32.